Home

Radiopharm Theranostics (ASX:RAD) to start prostate cancer trial

PUBLISHED

2022-07-11

Content

Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's portfolio of therapies.